The state of Florida currently has 16 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/23/2023
Locations: University of Florida College of Medicine, Gainesville, Florida +6 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Recruiting
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/28/2023
Locations: Site 210, Sarasota, Florida
Conditions: Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Recruiting
The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/16/2023
Locations: Site 02, Miami Lakes, Florida +1 locations
Conditions: Non-alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Excel Medical Clinical Trials, LLC, Boca Raton, Florida +16 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)